Treatment Use of 3,4-Diaminopyridine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol provided 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with congenital myasthenic syndrome (CMS). It is now closed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia

NCT03062631

Congenital Myasthenic Syndrome

NO_LONGER_AVAILABLE

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950

Lambert-Eaton Myasthenic Syndrome Congenital Myasthenic Syndrome

APPROVED_FOR_MARKETING

Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome

NCT01373333

Lambert-Eaton Myasthenic Syndrome

NO_LONGER_AVAILABLE

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

NCT00004832

Lambert-Eaton Myasthenic Syndrome

COMPLETED NA

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

NCT01511978

Lambert-Eaton Myasthenic Syndrome Eaton-Lambert Myasthenic Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CMS diagnoses were made based on clinical, electrophysiologic and molecular genetic findings. All patients were referred to the PI for DAP treatment. This study enrolled minors and adults.

CMS patients under age 18 years were included if their parent or guardian gave written permission. Minors who turned 18 while in the program were re-consented as adults.

The dose of DAP was determined individually for each patient. Adults were started with a dose of 10 mg 3-4 times daily, increased over several weeks to the dose that produced the maximum symptomatic response, not to exceed 100 mg daily. Pyridostigmine bromide (PB) was often added at low doses and increased to the dose that produced the best response, not to exceed 360 mg daily. In children, equivalent doses of these medications were calculated on a surface area basis. The doses of DAP and PB were periodically adjusted to assure that the smallest effective doses are used.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myasthenic Syndromes, Congenital

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3,4-diaminopyridine

Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DAP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of congenital myasthenic syndrome (CMS)
* Women of childbearing potential must have negative pregnancy test and agree to practice adequate contraception while taking DAP
* Must be competent to give consent

Exclusion Criteria

* Known seizure disorder
* Pregnancy
* Known cardiac arrhythmia or evidence of significant arrhythmia on screening ECG
* Known hepatic, renal or hematologic disease

Eligible Sex

ALL

Accepts Healthy Volunteers

No